Sonus/Abbott
This article was originally published in The Gray Sheet
Executive Summary
Enter agreement under which Abbott will manufacture privately held Sonus Pharmaceuticals' first product line, the EchoGen echocardiology and general radiology ultrasound contrast agents, according to a July 13 press release. Terms of the deal were not disclosed. Sonus plans to market the agents itself in the U.S. and is in discussions with more than one firm for international distribution. Sonus plans to begin EchoGen clinical trials by the end of the year....
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.